The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas.
Metastasectomy
Metastatic lung tumor
Neutrophil-to-lymphocyte ratio (NLR)
Sarcoma
Survival rate
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
12
02
2020
accepted:
17
06
2020
pubmed:
5
8
2020
medline:
16
6
2021
entrez:
5
8
2020
Statut:
ppublish
Résumé
Sarcomas are among the most refractory malignant tumors and often recur as pulmonary metastasis. Although the presence of a high neutrophil-to-lymphocyte ratio (NLR) has been associated with the prognosis of several malignancies, the relationship between the NLR and sarcoma with pulmonary metastasis is unclear. We investigated the impact of the NLR in patients who underwent surgical resection for metastatic lung tumors from various sarcomas. The subjects of this retrospective study were 158 patients with metastatic lung tumors from various sarcomas, who underwent initial pulmonary metastasectomy between 2006 and 2015. We examined the clinicopathological variables, including the NLR and the characteristics of surgical procedures. Survival was estimated by the Kaplan-Meier method and prognostic factors were evaluated by multivariate analysis. Multivariate analysis revealed significantly better survival of the group with an NLR < 2.26 immediately before the most recent pulmonary metastasectomy, in addition to such factors as the largest resected lesion being < 22 mm, a disease-free interval of > 2 years, and 3 or more pulmonary metastasectomies. The NLR immediately before the most recent pulmonary metastasectomy is a novel independent prognostic factor, which may be helpful when considering repeated pulmonary metastasectomy.
Identifiants
pubmed: 32747982
doi: 10.1007/s00595-020-02093-5
pii: 10.1007/s00595-020-02093-5
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-135Références
Ferrari A, Dirksen U, Bielack S. Sarcomas of soft tissue and bone. Prog Tumor Res. 2016;43:128–41.
pubmed: 27595362
pmcid: 27595362
Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of tumors of soft tissue and bone. Cancer. 2014;120:1763–74.
pubmed: 24648013
Marulli G, Mammana M, Comacchio G, Rea F. Survival and prognostic factors following pulmonary metastasectomy for sarcoma. J Thorac Dis. 2017;9:S1305–15.
pubmed: 29119019
pmcid: 5653498
von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:536–63.
Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, et al. NCCN guidelines insights: bone cancer, version 2.2017. J Natl Compr Canc Netw. 2017;15:155–67.
pubmed: 28188186
Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602–12.
pubmed: 10235518
pmcid: 1420804
Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.
pubmed: 9011700
Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D'Angelo SP, et al. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J Thorac Cardiovasc Surg. 2017;154:319–330.e1.
pubmed: 28395901
pmcid: 5521256
Dancsok AR, Asleh-Aburaya K, Nielsen TO. Advances in sarcoma diagnostics and treatment. Oncotarget. 2017;8:7068–93.
pubmed: 27732970
Kawai A, Yonemori K, Takahashi S, Araki N, Ueda T. Systemic therapy for soft tissue sarcoma: proposals for the optimal use of pazopanib, trabectedin, and eribulin. Adv Ther. 2017;34:1556–711.
pubmed: 28547734
pmcid: 5504216
Kondo H, Okumura T, Ohde Y, Nakagawa K. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes. Int J Clin Oncol. 2005;10:81–5.
pubmed: 15864692
Reza J, Sammann A, Jin C, Horvai A, Hudnall M, Jablons DM, et al. Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma. J Thorac Cardiovasc Surg. 2014;147:1193–201.
pubmed: 24507991
Schur S, Hoetzenecker K, Lamm W, Koestler WJ, Lang G, Amann G, et al. Pulmonary metastasectomy for soft tissue sarcoma—report from a dual institution experience at the Medical University of Vienna. Eur J Cancer. 2014;50:2289–97.
pubmed: 24997493
Chudgar NP, Brennan MF, Tan KS, Munhoz RR, D'Angelo SP, Bains MS, et al. Is repeat pulmonary metastasectomy indicated for soft tissue sarcoma? Ann Thorac Surg. 2017;104:1837–45.
pubmed: 29074153
pmcid: 5696033
Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19:2.
pubmed: 28057046
pmcid: 5217326
Omichi K, Cloyd JM, Yamashita S, Tzeng CD, Conrad C, Chun YS, et al. Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma. Surgery. 2017;162:752–65.
pubmed: 28688518
Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266:339–45.
pubmed: 27631774
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
pubmed: 23208313
pmcid: 23208313
Harrell FE Jr. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. Heidelberg New York Dordrecht London: Springer; 2015. p. 72.
Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017;10:12.
pubmed: 28057051
pmcid: 5217256
Biermann JS. Updates in the treatment of bone cancer. J Natl Compr Canc Netw. 2013;11:681–3.
pubmed: 23704242
Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7.
pubmed: 27148438
pmcid: 27148438
Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20.
pubmed: 27891213
pmcid: 27891213
Group ESESNW. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 suppl 3:iii102–iii112.
Group ESESNW. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 suppl 3:iii113–iii123.
Kruger M, Schmitto JD, Wiegmann B, Rajab TK, Haverich A. Optimal timing of pulmonary metastasectomy—is a delayed operation beneficial or counterproductive? Eur J Surg Oncol. 2014;40:1049–55.
pubmed: 24746934
Stephens EH, Blackmon SH, Correa AM, Roth JA, Rice DC, Hofstetter W, et al. Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients. J Am Coll Surg. 2011;212:821–6.
pubmed: 21435923
Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, et al. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015;112:103–6.
pubmed: 26179670
Welter S, Grabellus F, Bauer S, Schuler M, Eberhardt W, Totsch M, et al. Growth patterns of lung metastases from sarcoma: prognostic and surgical implications from histology. Interact Cardiovasc Thorac Surg. 2012;15:612–7.
pubmed: 22761121
pmcid: 3445364
Welter S, Arfanis E, Christoph D, Hager T, Roesel C, Aigner C, et al. Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size? Eur J Cardiothorac Surg. 2017;52:39–46.
pubmed: 28402510
Sato T, Iguchi T, Hiraki T, Gobara H, Fujiwara H, Sakurai J, et al. Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients. Jpn J Radiol. 2017;35:61–7.
pubmed: 27864664